Rapport Therapeutics logo

Rapport Therapeutics, Inc.

Biotechnology

Rapport Therapeutics Stock

Rapport Therapeutics is a biotechnology company focused on developing precision medicines for neurological disorders. It utilizes receptor-associated proteins to identify small molecule drugs that modulate neurotransmitter receptors, aiming for greater efficacy and reduced side effects.

For more Rapport Therapeutics stock information, or to buy or sell private shares, sign up for a MicroVentures account.

Management Team

Abraham Ceesay Chief Executive Officer
Troy Ignelzi Chief Financial Officer
Swamy Yeleswaram, Ph.D. Chief Development Officer
Karina Chmielewski Chief Information Officer & Head of Operations
Kathy Wilkinson Chief People Officer
David Bredt, Ph.D. Co-Founder & Chief Scientific Officer
Steven Paul, MD Co-Founder & Chairman
Brad Galer, MD Chief Medical Officer
Cheryl Gault Chief Operating Officer

Funding Information